Skip directly to content

Corporate Partnerships July to December 2011

on Wed, 06/08/2016 - 22:44

Alzheimer’s Australia

Alzheimer’s Australia is the peak body providing support and advocacy for the 269,000 Australians with dementia and the million Australians who care for them. The organisation supplies information, support, education, counselling and helpline services and provides leadership in policy and services. Through Alzheimer’s Australia, research grants are provided to emerging researchers. Alzheimer’s Australia’s vision is for a society committed to the prevention of dementia whilst valuing and supporting people living with the condition.
Pfizer Australia provided funding to Alzheimer’s Australia to:

  • Support the National Consumer Advocacy Committee. This Committee is made up of people living with dementia, their families and carers. The broad purpose of the Committee is to build a consumer focus into the work of Alzheimer’s Australia and its state and territory member organisations. ($30,000)
  • Support Alzheimer’s Disease International Conference. ($5,000)
  • Support Alzheimer’s Australia National Conference. ($20,000)
  • Support a new Community Service Announcement to increase awareness and understanding of dementia to Australians (involves a media campaign). ($95,000)
  • Refresh the Alzheimer’s Australia website to include relevant carer information to educate carers about the Alzheimer’s Disease patient journey. ($5,000)
  • Support the development of the Alzheimer’s Australia Memory-Loss website. ($48,491)


Arthritis Australia

Nearly one in five Australians (3.85 million people) has arthritis. They are represented by Arthritis Australia the peak arthritis organisation in Australia and supported by affiliate offices in each State and Territory. Arthritis Australia also delivers support, awareness and education activities to people living with arthritis, as well as their carers, families and friends. Customised programs are also delivered to GPs, allied health professionals and community workers both in metropolitan and rural settings.
Arthritis Australia also promotes arthritis awareness and advocates for improvements for Australians living with arthritis to business leaders, federal politicians, their advisers, and Government officials. Through the Arthritis Australia National Research Program emerging researchers receive funding support to progress their work in gaining a greater understanding of arthritis and associated musculoskeletal discussions, as well as the long-held hope for a cure.  
In 2011 Pfizer Australia supported the Osteoarthritis (OA) Clinical Excellence Hub website with $30,000. This microsite will assist patients and their treatment advisors to more effectively:

  • Diagnose OA.
  • Manage the pain, inflammation and other symptoms associated with OA.
  • Help improve mobility and enhance quality of life.
  • Slow disease progression and reduce costly long term OA complications.

This project will help address several issues identified in a recent survey: The Ignored Majority – The Voice of Arthritis 2011 survey.
Pfizer also sponsored:

  • The cost of reprinting an Osteoarthritis booklet to educate consumers and GPs about osteoarthritis: $11,000.
  • The Voice of Arthritis report as part of the Medicines Australia Community Chest project: $15,000.

Total: $56,000

Chronic Pain Australia

Chronic Pain Australia is a health promotion charity based in Sydney. Its mission is to reduce the unnecessary suffering and isolation caused by chronic pain in the Australian community. Its core objectives are to: destigmatise chronic pain through developing advocacy programs, prevent isolation (by developing support and information services) and improve knowledge about chronic pain for the whole community including people in pain and their families, as well as health professionals (by organising educational initiatives).
In 2011 Pfizer supported Chronic Pain Australia’s inaugural National Pain Week with $10,000. Chronic Pain Australia developed National Pain Week to create awareness and to educate people living with pain and their carers, treatment providers, governments and the general public. Pfizer supported this media campaign which focused on issues faced by people in pain, controlling pain, treatment options and counselling.
Total: $10,000

Haemophilia Foundation of Australia

Haemophilia Foundation Australia (HFA) represents people with haemophilia, von Willebrand disorder and other related inherited bleeding disorders, and their families through:

  • Advocacy and Representation.
  • Education.
  • Research.
  • HFA works with a network of state and territory foundations and specialist health professionals groups to ensure all people with bleeding disorders in Australia have access to the world’s best practice treatment and care. HFA is a National Member Organisation of the World Federation of Haemophilia and participates in activities to improve access to treatment and care to people with bleeding disorders around the world.

 In 2011 Pfizer supported the establishment of a Nurses Education Award with a grant of $10,000 to HFA for the Australian Haemophilia Nurses Group (AHNG) to encourage specialist haemophilia nursing services in haemophilia centres around Australia. The nurses awards are available to nurses who are members of the AHNG to support their continuing education.
Total: $10,000

Immunisation Alliance WA

Immunisation Alliance Western Australia (IAWA) is a not-for-profit, community-based organisation committed to raising awareness in the community about the benefits of immunisation and assisting parents to make informed decisions about vaccines for their children.
In 2011 Pfizer supported the IAWA’s corporate launch.
Total: $1,500

Mental Health Council of Australia (MHCA)

The Mental Health Council of Australia (MHCA) is the peak, national non-government organisation representing and promoting the interests of the Australian mental health sector, committed to achieving better mental health for all Australians. Its mission is to achieve better mental health in Australia through strategic engagement in policy, practice and research.
In 2011 Pfizer supported MHCA by funding the MHCA Pharma Collaboration. The Collaboration aims to operate under the general guidelines and principles set out in the document Working Together: A Guide for Relationships between Health Consumer Organisations and Pharmaceutical Companies.
The MHCA Pharma Collaboration’s mission statement is: ‘The Pharmaceutical Industry and MHCA working together to support consumers, carers and health professionals to improve the quality of mental health care and outcomes for people with mental health problems by promoting the development and effective implementation of mental health policy.’
In 2011-12 Pfizer has provided funding towards the following MHCA Collaboration projects:
Quality Use of Medicines project.
Indigenous Co-morbidity Publication and Launch.
World Mental Health Day advertisements. 

Total: $26,000

Prader-Willi Syndrome Association of Victoria

The Prader-Willi Syndrome Association of Victoria was established in 1978 by parents of children affected by the syndrome and is run entirely by volunteers. PWSA Victoria is a support group that provides awareness, education and support to families living with Prader-Willi Syndrome to ensure better quality of life for persons with PWS and their families. Their members include parents and carers, family members, people with PWS, medical professionals, educators and interested supporters.
In 2011 Pfizer Australia supported PWSA Victoria by funding a family day for families of children with PWS which provided an opportunity for the families to share experiences and obtain valuable information on PWS.
Total: $5,500

Pulmonary Hypertension Society of Australia and New Zealand

The Pulmonary Hypertension Society of Australia and New Zealand is a not-for-profit organisation with a mandate to advocate for a sustainable ‘model of care’ with equitable access to skilled clinicians that allows timely diagnosis, treatment and ongoing management for patients with Pulmonary Hypertension in Australia and New Zealand.
Pulmonary Hypertension is a relatively rare disease considered to be present in between 15 – 55 patients per million people of the general population in its rarest form of Pulmonary Arterial Hypertension (PAH). This has substantively increased from historical data suggesting only 1-2 patients per million in the general population. Pulmonary Hypertension is however more of an ‘umbrella’ disease encompassing more common forms of associated Pulmonary Hypertension affecting much larger numbers of patients. Recent Australian data suggests that pulmonary hypertension, in all its forms, may affect up to 5,000 people per million or 500 in every 100,000 people in Australia. The primary symptom in patients presenting to primary care is ‘shortness of breath’ (SOB). SOB is a universal symptom which may reflect any number of more common underlying diseases, eg asthma, congestive cardiac failure, coronary heart disease, chronic lung diseases, anaemia and many more making the diagnosis of the much more rare disease of PAH difficult.
The four areas of focus for the Society are:

  • Workforce sustainability. Sustainable models of care require specialist PH physicians with a passion for this area of medicine. Ensuring that there is a network of research opportunities, and an education platform that meets the training needs of physicians with an interest in PH will work some way toward a standardised ‘model of care’ encouraging young physicians to become interested in pursuing a career involving PH.
  • Ongoing PH education. Timely access to skilled physicians requires more specialists with in depth knowledge and expertise in the diagnostic challenges and ongoing management nuances that present in PH patients, as with any chronic and complex disease. The PHSocANZ will work with the ANZ community to expand the knowledge base of PH and the complexities of diagnosis and management of this group of patients. We intend to expand the reach into cardiology, respiratory medicine, immunology, rheumatology, intensivists, anaesthetist, cardiac surgeons and the advances trainees and allied health that accompany each speciality.
  • Collaborative research. To continue to advance our knowledge and expertise requires ongoing research. The society plans to set up a National PH Registry (NPHR) that covers the diverse associated aetiologies of PH. The registry will provide a platform for research and improve our understanding of all forms of PH.
  • Lobbying power. By coming together the society hopes to create a force that will have levels of influence on many facets of PH management in Australia and New Zealand. We would hope to represent clinicians and allied health professionals to Government and others (e.g RACP) to be of assistance in policy reviews effecting PH management and treatment. Such items may include a PBS funded combination therapy in the future. We will work with the Pharmaceutical industry and government to promote the achievement of our goals.

In 2011 Pfizer Australia supported the PHSocANZ towards achieving these four goals.
Total: $50,000

Royal Australian and New Zealand College of Ophthalmologists (RANZCO) and The Eye Foundation

The Eye Foundation is the medical eye specialists’ foundation, dedicated to restoring sight and preventing vision loss throughout Australasia. The Eye Foundation is a not-for-profit eye health organisation. It represents more than 890 Australian and New Zealand medical eye specialists (ophthalmologists) who are passionate about giving future generations the best vision possible. The Foundation was founded in 2002 as the fundraising arm of The Royal Australian and New Zealand College of Ophthalmologists (RANZCO) and The Ophthalmic Research Institute of Australia (ORIA).
In 2011 Pfizer Australia supported the Eye Foundation by funding several projects. These included: ANZRAG medical research; Rural, Remote and Indigenous Eye Care Program, educational scholarships, registrar travel grants, film and poster awards, and sponsorship of the RANZCO 2011 Congress in Canberra.
Total: $222,000